Physician profile
Vicky Leoni
NPI 1770257743
$3,529.74
in general payments reported to CMS, 2019-2025
34 companies · $965 in 2025
The $965 reported for 2025 was more than what 84% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $441 · 2023: $933 · 2024: $820 · 2025: $965.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,717.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,048.85 | 2022-2025 | |
| Madrigal Pharmaceuticals | $328.54 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $214.22 | 2021-2025 | Entyvio, Gattex |
| Phathom Pharmaceuticals, INC. | $188.10 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $168.04 | 2023-2025 | Ibsrela |
| Celgene Corporation | $135.63 | 2023-2024 | Zeposia |
| Astellas Pharma US INC | $115.16 | 2021 | |
| Merck Sharp & Dohme LLC | $113.99 | 2021-2023 | Gardasil 9, Dificid, Zinplava |
| Amgen INC. | $113.86 | 2021-2025 | Uplizna |
| Ironwood Pharmaceuticals, INC | $96.46 | 2023-2024 | Linzess |
| Sunovion Pharmaceuticals INC. | $93.04 | 2021-2022 | |
| Glaxosmithkline, LLC. | $90.27 | 2021-2023 | Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $89.37 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $62.14 | 2023-2025 | Ingrezza, Ongentys |
| Vertex Pharmaceuticals Incorporated | $62.01 | 2025 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicky Leoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.